Germ cell tumors carry an excellent prognosis with platinum-based therapy upfront. The patients who either relapse or demonstrate refractoriness to platinum pose a challenge. There exist many reports in the literature on the use of high-dose chemotherapy and stem cell rescue improving the outcome in patients with relapsed germ cell tumors. However, the reports have great variability in the patient selection, prior treatments, the choice of the conditioning regimen and variability of the doses within the same regimen. In this report, we present 37 patients who underwent a uniform protocol of high-dose chemotherapy with stem cell rescue. Stem cell mobilization was performed with high-dose CY (4 g per m 2 ) and we were able to collect adequate cells for marrow rescue in all patients. Patients received a high-dose regimen with etoposide (800 mg/m 2 per day) days À6, À5 and À4 as a continuous infusion, carboplatin (667 mg/m 2 per day) on days À6, À5 and À4 as a 1 h infusion, and CY (60 mg/kg per day) on days À3 and À2. In this high-risk group of patients, high-dose chemotherapy with autologous stem cell rescue led to a 3-year overall survival of 57% and a 3-year event-free survival of 49%. The results are reflective of a single procedure. No tandem transplants were performed. The treatment-related mortality was low at 3% in this heavily pretreated group.
Introduction
Since the introduction of cisplatin, outcome for patients with germ cell tumors has improved tremendously. Patients with metastatic testicular cancer will achieve cure rates of over 70% with the use of a cisplatin-based regimen. 1 Salvage chemotherapy plays an important role in those patients who either are refractory to cisplatin or who relapse after initial treatment. However, timing for the use of high-dose chemotherapy instead of standard salvage chemotherapy is less well defined and patient heterogeneity plays an important role in the overall outcome. An effort has been made to identify various prognostic groups to identify high-risk patients upfront, but since only 30% of patients with germ cell tumors will require salvage treatment, studies have been limited. 2 The use of initial high-dose chemotherapy in patients with poor risk disease has not been shown to be superior to standard chemotherapy; therefore high-dose chemotherapy with hematopoietic stem cell rescue remains the treatment of choice for patients who fail standard salvage therapy. [2] [3] [4] There are many controversies and unresolved issues on the use of high-dose chemotherapy in germ cell cancer. They include the lack of consensus on which preparative regimen to be utilized as the high-dose chemotherapy before stem cell rescue, whether standard salvage chemotherapy should be used before high-dose chemotherapy, and the use of tandem transplants as initial or salvage treatment. 5 We report our experience at the Stem Cell Transplantation Program at Stanford University Medical Center utilizing a uniform high-dose preparative regimen with carboplatin, etoposide and CY.
Patients and methods
We conducted a review of the medical records of 37 consecutive patients who received high-dose chemotherapy (HDCT), followed by autologous hematopoietic SCT (HSCT) between 1995 and 2005 at Stanford University Medical Center using medical charts and electronic medical records. The first 33 patients were treated on a research protocol, and the last four patients were treated as per the protocol after it finished accrual. Appropriate Institutional Review Board guidelines were followed.
All patients received a cisplatin-based chemotherapy regimen initially and surgery for residual disease when appropriate. Patients were followed by the primary oncologist and at relapse generally received salvage chemotherapy, consisting of standard cisplatin-and ifosfamide-containing regimens. Risk stratification at the time of high-dose chemotherapy was based upon the prognostic model for conventional dose salvage according to Fossae t al. 6 No CR to first-line treatment, progression-free interval o2 years and a-fetoprotein 4100 000U/l or human chorionic gonadotropin 4100 U/l at initiation of salvage.
Treatment consisted of HDCT followed by hematopoietic stem cell rescue with a minimum dose of 3 Â 10 6 CD34-positive cells per kg. Exclusion criteria for HDCT included a Karnofsky performance status of o80%; creatinine clearance o50 ml/min; cardiac ejection fraction o40%; pulmonary diffusion capacity with carbon monoxide o50% of predicted; transaminases more than twice the upper limit of normal; or serologies positive for hepatitis B surface antigen, hepatitis C or HIV.
PBSCs were mobilized by the administration of highdose CY (4 g per m 2 ), followed by G-CSF at a dose of 10 mg/kg per day. The apheresis procedure was performed upon ANC recovery, and 3-6 Â 10 6 CD34-positive cells were collected as per institutional guidelines. The apheresis product was cryopreserved in dimethylsulfoxide according to the institutional standard operating procedures (SOPs).
All patients received a preparative regimen, consisting of etoposide (800 mg/m 2 per day) on days À6, À5 and À4 as a continuous infusion, carboplatin (667 mg/m 2 per day) on days À6, À5 and À4 as a 1 h infusion, and CY (60 mg/kg per day) intravenously over 2 h on days À3 and À2. The cryopreserved stem cell units were thawed and infused intravenously on day 0 according to institutional SOPs. All patients received G-CSF intravenously at a dose of 5 mg/kg per day after transplant until the ANC was greater than 2 Â 10 9 per liter for 2 consecutive days. Patients were treated on the SCT unit in high-efficiency particulate air-filtered rooms and all supportive care guidelines were followed according to institutional SOPs.
EFS and overall survival (OS) were estimated by the Kaplan-Meier method using log-rank tests (SPSS 16.0, Chicago, IL). Events were defined as graft failure, relapse or death.
Results

Patient characteristics
Patient characteristics at the time of diagnosis are listed in Table 1 . A total of 37 patients were treated on this protocol. Four patients were in the pediatric age range. The Table 1 Patient characteristics and univariate analysis of outcomes Stem cell rescue for high-risk germ cell tumors R Agarwal et al median age was 28 years (range, 9-59 years). There were 34 men and 3 women. Of 37 patients, 31 were mixed nonseminomatous histology and 6 patients had pure seminoma. Twenty-four patients had primary location in the gonads, whereas ten patients had an extragonadal primary and three patients had primary pituitary germ cell tumors. Only one patient had stage 1 disease at initial diagnosis and received HDCT with stem cell rescue, whereas the majority (23 of 37) of patients had stage 3 disease at presentation. Twenty-seven patients had evidence of progressive disease or incomplete response after two cycles of conventional salvage chemotherapy, indicating the aggressive nature of the disease.
Total number 3-year RI (95% CI) P-value 3-year EFS (95% CI) P-value 3-year OS (95% CI) P-value
At the time of diagnosis, 29 patients received 4 cycles of platinum-based induction chemotherapy, and 8 patients were given an additional chemotherapy because of failure to achieve remission with standard four cycles of chemotherapy. Upon relapse, 29 patients received salvage chemotherapy before HSCT whereas 8 patients received HDCT with stem cell rescue without prior salvage chemotherapy. Of the 29 patients who received salvage, 4 were platinum insensitive as defined as a relapse within 1 month of receiving cisplatin. There were no patients who were absolutely refractory to cisplatin, as defined by rising tumor markers or increase in tumor while receiving cisplatin chemotherapy.
Engraftment and toxicity
After receiving HDCT with autologous hematopoietic stem cell rescue, patients were analyzed for toxicity and engraftment. The median time of engraftment with an ANC above 0.5 Â 10 9 per liter was 10 days (range, 7-18 days). The median time of engraftment with a platelet count above 20 Â 10 9 per liter without a transfusion for 3 days was 15 days (range, 8-31 days). Nonrelapse mortality at 100 days post transplant was 5% (95% CI: 1-19%). One patient died of respiratory failure (unknown etiology) within 30 days of transplant, and one patient died of secondary acute myeloblastic leukemia associated with a t(9;11)(p22;q23). Treatment-related mortality was 3% (95% CI: 1-15%).
All patients developed oropharyngeal mucositis; however, the incidence of grade 3 or 4 mucositis was only 11% (95% CI: 5-25%). All patients developed gastrointestinal toxicity manifested as a variable degree of persistent nausea and poor appetite. Patients generally took 3-10 weeks before they showed signs of complete recovery with elimination of nausea and improving appetite. Four patients (11%; 95% CI: 5-25%) developed signs of mild veno-occlusive disease (VOD) of liver that were managed with diuretic therapy alone. There were no deaths or intensive care admissions because of severe VOD.
Outcome
In this high-risk group of patients, autologous hematopoietic stem cell rescue following HDCT led to a 3-year OS of 57% (95% CI: 41-71%), as shown in Figure 1 , and a 3-year EFS of 49% (95% CI: 33-64%), as shown in Figure 2 . The relapse rate was 46% (95% CI: 21-62%).
We performed univariate analysis to evaluate for possible factors relating to successful outcomes following HDCT with autologous HSCT. There was no significant difference in 3-year EFS or OS depending upon patient sex, age at transplant, original stage, risk stratification at relapse, phase of disease at transplant (CR vs PR) or number of prior chemotherapy regimens (Table 1) . Interestingly, we identified no significant difference in 3-year EFS between patients with primary mediastinal disease vs a nonmediastinal primary tumor, or in patients with gonadal vs extragonadal disease. As shown in Figure 3 , there was a slight trend toward improved 3-year EFS in patients with pure seminoma, but because of small numbers, this did not reach statistical significance (P ¼ 0.09). There were only eight patients who did not receive salvage chemotherapy before HDCT, and the OS of these patients appears to be similar to the patients who received salvage chemotherapy (3-year OS 62 vs 55%, Figure 4 ). 
Discussion
Germ cell tumors carry excellent prognosis with first-line platinum-based chemotherapy. For patients who relapse after the first-line chemotherapy or prove to be platinumrefractory, several salvage chemotherapy regimens have been described. 2, 7 HDCT with autologous hematopoietic stem cell rescue has been used both in initial salvage as well as in salvage-refractory patients with variable success. 4, 8, 9 In the past 10 years, there have been several reports published on the use of high-dose chemotherapy with autologous stem cell rescue in recurrent, relapsed germ cell tumors. These reports are consistent in providing information on the superiority of high-dose chemotherapy compared to conventional chemotherapy. However, the reports have great variability in patient selection, prior treatments, the choice of the conditioning regimen and variability of the doses within the same regimen. Also, some reports describe the efficacy of a single HDCT cycle, whereas others utilize a tandem transplant strategy. 4 ,5,10,11 Table 2 summarizes the largest reports on a single round of HDCT with autologous stem cell rescue for treatment of patients with refractory disease. The first two studies by Motzer et al. 12, 13 describe the use of HDCT in high-risk patients. In the initial series, all refractory patients were enrolled. These patients were heavily pretreated with chemotherapy. The high treatment-related mortality and lower EFS is represented in these results. The subsequent study enrolled relapsed and refractory patients who received only two cycles of salvage chemotherapy and these patients achieved better survival and experienced less toxicity. Rick et al. 3 described results of salvage therapy with paclitaxel, ifosfamide and cisplatin followed by conditioning with carboplatin, etoposide and thiotepa with OS of 26%. Studies by Mandanas et al. 14 reported on 21 patients a 52% disease-free survival in relapsed patients with germ cell tumors. Chaudhary et al. 9 reported on 24 patients using a three drug preparative regimen an OS of 38% in a similar group of patients. Paclitaxel-containing high-dose chemotherapy regimens have also been used with similar results.
15, 16 Rick et al. 17 report the use of Paclitaxel in the salvage protocols followed by high-dose chemotherapy with carboplatin, etoposide and thiotepa. OS of these high-risk patients was 39%, but about a third of these patients experienced neurotoxicity, possibly because of the high doses of carboplatin and thiotepa. Overall, the most common high-dose chemotherapy regimen has been with carboplatin, etoposide and CY, although there is a significant dose variation within these regimens making it difficult to compare them.
Some centers advocate the use of tandem transplants. Broun et al. 5 reported 25 patients with testicular germ cell tumors in first relapse who were treated with a conditioning regimen of carboplatin and CY, followed by autologous HSCT. This approach resulted in progression-free survival of 52% at 26 months follow-up. Mu¨ller et al. 10 published their data from either single or tandem transplants with much superior results, indicating a 5-year OS of 73%. The results from tandem transplants are variable and many reports have either combined the data from single and tandem transplants or the numbers are very small. Therefore, the superiority of tandem transplants over single HSCT is not yet established.
We describe 37 patients diagnosed with relapsed or refractory germ cell tumors who underwent high-dose chemotherapy with carboplatin, etoposide and CY, followed by autologous hematopoietic stem cell rescue with a 3-year EFS and OS of 49 and 57%, respectively. One limitation of our study is that these patients had mixed characteristics, though most of them were very high risk based upon their tumor markers and relapse patterns. Perhaps our results are slightly better because of the small number of patients who are cisplatin insensitive upon entry to HDCT. As supported by the literature, patients with pure seminoma appeared to have the best outcome. 13 Of the six high-risk seminoma patients who underwent HDCT and autologous HSCT, five patients are long-term survivors. It should be noted that our patients received only a single HDCT with autologous rescue as opposed to reports describing tandem transplants. The treatment-related Stem cell rescue for high-risk germ cell tumors R Agarwal et al mortality was low, despite the fact that the majority of patients were heavily pretreated. Overall, our regimen was well tolerated with an acceptable toxicity profile. The patients engrafted with ANCs above 500 at a median of 10 days and platelet transfusion independence was achieved at a median of 15 days. Nonrelapse mortality at day 100 post transplant was 5%, with one patient death because of diffuse alveolar hemorrhage and respiratory failure. In addition, one patient developed a rapidly progressive case of 11q23-associated AML and died on day þ 75 following HSCT. Given the usual 2-to 3-year latency period of epipodophyllotoxin-related AML 18 , it seems likely that the inciting cause was the etoposide-based chemotherapy received at the time of diagnosis 2 years earlier, rather than the HDCT utilized in this protocol. Therefore, the treatment-related mortality incidence was only 3%. The incidence of VOD was 11%, with most patients developing only mild disease. This data are within the published experience of liver injury following autologous transplants. 19, 20 The only prominent toxicity was grades 3 and 4 mucosal injury in 20% of the patients, and slow recovery of the gastrointestinal tract manifested as prolonged nausea and poor oral intake in most of the patients.
After analysis of our institutional data and reviewing the literature, it seems clear that HDCT with autologous hematopoietic stem cell rescue provides good results in high-risk germ cell tumor patients. However, the optimum timing of HDCT is not determined. The regimen of carboplatin, etoposide and CY at these doses is well tolerated with an acceptable toxicity profile, and provides encouraging results when given for patients with high-risk germ cell tumors. Further randomized studies will be needed to determine if tandem transplants are superior to a single transplant utilizing an optimal conditioning regimen, such as the one described in this study.
